ストックスクリーナーアプリを入手
4.87
2.99%
-0.15
アフターアワーズ：
4.88
0.010
+0.21%
前日終値:
$5.02
開ける：
$5.05
24時間の取引高:
2.84M
Relative Volume:
0.47
時価総額：
$898.67M
収益：
-
当期純損益:
$-26.86M
株価収益率:
-19.81
EPS:
-0.2458
ネットキャッシュフロー:
$-28.39M
1週間 パフォーマンス:
-0.20%
1か月 パフォーマンス:
+17.92%
6か月 パフォーマンス:
+189.88%
1年 パフォーマンス:
+184.80%
1日の値動き範囲:
$4.825
$5.055
1週間の範囲:
$4.655
$5.235
52週間の値動き範囲:
$1.36
$6.14
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
名前
Sellas Life Sciences Group Inc
セクター
電話
(646) 200-5278
住所
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
4.87 | 926.35M | 0 | -26.86M | -28.39M | -0.2458 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-07-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 開始されました | Oppenheimer | Outperform |
| 2018-04-02 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-19 | アップグレード | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc (SLS) 最新ニュース
SLS stock kicks off week in green: CEO flags role in EU biotech policy talks that could impact drug approvals - MSN
SLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvals - Stocktwits
SLS stock slips after-hours as cancer pipeline silence frustrates retail — China licensing fight now in spotlight - MSN
SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits
SLS stock gains momentum: NVDA, MSFT investor loads up ahead of AML trial milestone trigger - MSN
Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN
SLS News | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SLS stock sparks retail buzz ahead of AACR presentation on experimental cancer therapy - MSN
SLS stock jumps premarket: US investor Dagco boosts stake by 78% ahead of fresh cancer drug data reveal - MSN
SLS Forecast, Price Target & Analyst Ratings | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SLS stock jumps overnight: ‘potent’ AML drug data ahead of cancer summit fuels fresh momentum - MSN
SELLAS Life Sciences Group (SLS) price target increased by 15.38% to 10.20 - MSN
SELLAS LIFE SCIENCES GROUP, INC. (SLS) - MSN
SLS stock rises premarket ahead of cancer summit this month – investors eye phase 3 AML trial milestone - MSN
SELLAS Life Sciences Group (SLS) price target increased by 26.83% to 8.84 - MSN
SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger - Stocktwits
SLS stock jumps overnight: CEO doubles down on ‘steadfast’ confidence in AML drug and pushes for 20M share plan approval - MSN
SLS stock rallies ahead of AML trial readout — 'Pharma Bro' Martin Shkreli says he's still 'very bearish,' predicts drug will fail - MSN
SLS Stock Holds Support As Cash Pile Fuels Biotech Bounce - StocksToTrade
Wall Street analysts think SELLAS Life Sciences Group, Inc. (SLS) could surge 66.09%: Read this before placing a bet - MSN
SELLAS Life Sciences falls for fourth straight session — what’s driving the sell-off? - MSN
Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants - MSN
SLS Stock Jumps Overnight: CEO Doubles Down On ‘Steadfast’ Confidence In AML Drug And Pushes For 20M Share Plan Approval - Stocktwits
Sellas Life Sciences Group Inc (SLS) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):